Tolvaptan - Vasopressin Antagonist for Hyponatremia
, 2023 The groundbreaking TEMPO 3:4 trial, which served as the basis for tolvaptan's approval, represented a revolution in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Through this advancement, patient management for ADPKD has evolved from using broad strategies to stop the progression of chronic kidney disease to focusing on disease-
openaire +2 more sources
Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back [PDF]
, 2016 nephropathy, with an esti-mated prevalence of 1:1000. The disease is characterized by the development of multiple cysts from all nephron segments leading to the enlargement of both kidneys and replacement of normal parenchyma (see [1]).
Devuyst, Olivier +2 more
core
Ваптаны в лечении хронической сердечной недостаточности (ХСН) [PDF]
, 2013 Анализ научной медицинской литературы, содержащей информацию о новом классе препаратов "ваптаны" в терапии ...
Ефремова, О. А. +2 more
core
Nanoplasmonic sensing as a rapid and sensitive methodology to investigate tolvaptan loaded plant-derived nanovesicles and liposomes [PDF]
Plant-derived nanovesicles (PDNVs) are potential next generation carriers for drug delivery. However, the systemic incorporation of drugs into PDNVs and their quality control still needs extensive research. Previous works showed that Solanum lycopersicum
Chen, Rui +6 more
core +1 more source
Sulfonate and acetyl derivatives of the vasopressin antagonist tolvaptan: reactivity towards DNA and 2’-deoxynucleosides [PDF]
, 2015 Tolvaptan is an orally effective nonpeptide arginine vasopressin (AVP) V2-receptor antagonist, used in the treatment of clinically significant euvolemic and hypervolemic hyponatremia.
Fidalgo, Lara Gião
core
Treatment of renal congestion by tolvaptan [PDF]
Hypertension Research, 2019 Satoshi Kinugasa +2 more
openaire +3 more sources
Standard Poster Abstracts for the 17th Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions
Journal of Arrhythmia, Volume 41, Issue 2, April 2025.
wiley +1 more source
Tolvaptan, a Selective Oral Vasopressin V2 -Receptor Antagonist, for Hyponatremia [PDF]
, 2018 Berl, Tomas +7 more
core +1 more source
L\u2019IPONATRIEMIA NELL\u2019ANZIANO: UNA PROBLEMATICA SEMPRE ATTUALE [PDF]
, 2015 Le alterazioni della concentrazione plasmatica del sodio rappresentano una delle disionie di pi\uf9 frequente riscontro nei pazienti ricoverati e che l\u2019incidenza e la prevalenza aumentano con l\u2019et\ue0.
Barbagallo, M. +2 more
core
Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure [PDF]
, 2015 2015-08Although reports suggest that tolvaptan does not reduce survival or subsequent hospitalization rates in heart failure patients, its continuous use has shown good outcomes in some patients who cannot be effectively managed with high doses of loop ...
60360 +19 more
core